The company withdrew its application for the use of Jalra on its own and as an add-on to insulin during the assessment of the medicine.
Under vurderingen af lægemidlet trak virksomheden trak sin ansøgning om brug af Jalra som enkeltmiddelbehandling og som tillægsbehandling til insulin tilbage.